Clinical trial
Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
NCT07045168 is registered in ClinicalTrials.gov with FengYan Jin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
- Lead sponsor
- FengYan Jin
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- September 15, 2025
- Completion date
- July 4, 2029
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.